Antihypertensives & ARVs

Legend

↑                  Potential elevated exposure of the antihypertensive
↓                  Potential decreased exposure of the antihypertensive
↔                No significant effect
D                  Potential decreased exposure of ARV drug
E                  Potential elevated exposure of ARV drug

ATV/c         ATV co-formulated with COBI (300/150 mg qd)
DRV/c         DRV co-formulated with COBI (800/150 mg qd)
CAB/RPV   CAB and RPV im long acting injections (PK and/or QT interactions shown are with RPV)

Numbers refer to increased or decreased AUC as observed in drug-drug interaction studies

Note: although some drug interactions are predicted to potentially require a dosage adjustment based on the drug's metabolic pathway, clinical experience with a particular antihypertensive and ARV drug may indicate that dosage adjustments are not an a priori requirement

Interactions with ABC, FTC, 3TC, ZDV

ABC, FTC, ZDV:   no clinically relevant interactions expected.
3TC:                      increased 3TC exposure with atenolol and amiloride.
3TC:                      increased exposure of atenolol and amiloride.

Interactions with cabotegravir (oral)

None

Interactions with ibalizumab

None

Comments

1. Parent drug concentrations decreased but active metabolite increased.
2. Parent drug concentrations increased but active metabolite decreased.
3. Risk of PR interval prolongation.
4. ECG monitoring recommended.
5. Use with caution as both LPV and calcium channel blockers prolong the PR interval. Clinical monitoring is recommended.
6. Caution as both drugs can induce QT interval prolongation.
7. Use with caution in persons with a history of postural hypotension or on concomitant medicinal products known to lower blood pressure, and those at increased risk of cardiovascular events.
8. Hydralazine has some nephrotoxic potential. If co-administration is unavoidable, monitor renal function closely.

^ LEN causes moderate inhibition of CYP3A4 and, when discontinued, remains in the circulation for prolonged periods. Residual concentrations of LEN may affect the exposure of sensitive CYP3A4 substrates and/ or narrow therapeutic index drugs that are initiated within 9 months after the last subcutaneous dose of LEN.

Further Information

For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, please refer to: http://www.hiv-druginteractions.org (University of Liverpool)